Provided by Tiger Trade Technology Pte. Ltd.

IN8bio, Inc.

1.89
-0.0200-1.05%
Volume:61.12K
Turnover:116.42K
Market Cap:18.61M
PE:-0.43
High:1.99
Open:1.90
Low:1.82
Close:1.91
52wk High:7.50
52wk Low:1.17
Shares:9.85M
Float Shares:9.15M
Volume Ratio:1.21
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4441
EPS(LYR):-4.4441
ROE:-92.49%
ROA:-46.64%
PB:0.68
PE(LYR):-0.43

Loading ...

IN8BIO Announces Private Placement of Common Stock and Pre-Funded Warrants

Reuters
·
Dec 20, 2025

BRIEF-In8bio Announces Pricing Of Private Placement Of Up To $40.2 Million

Reuters
·
Dec 19, 2025

IN8bio Inc: Initial Proceeds Extend Cash Runway Into First Half of 2027

THOMSON REUTERS
·
Dec 19, 2025

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

GlobeNewswire
·
Dec 19, 2025

IN8bio Presents Promising Clinical Trial Results

TIPRANKS
·
Nov 25, 2025

IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial

Reuters
·
Nov 25, 2025

IN8BIO Showcases Advances in Gamma-Delta T Cell Therapies in New Corporate Presentation

Reuters
·
Nov 24, 2025

BRIEF-In8bio Inc Files For Mixed Shelf Offering Of Upto $200 Million - SEC Filing

Reuters
·
Nov 08, 2025

Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and IN8bio (INAB)

TIPRANKS
·
Nov 08, 2025

IN8Bio Reports Improved Financials Amid Ongoing Challenges

TIPRANKS
·
Nov 07, 2025

IN8bio Q3 EPS $(0.85) Beats $(1.25) Estimate

Benzinga
·
Nov 07, 2025

IN8bio Q3 net loss narrows to $3.9 mln, R&D expenses down

Reuters
·
Nov 07, 2025

IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University

Reuters
·
Nov 07, 2025

IN8BIO Reports Q3 2025 Results and Advances Gamma-Delta T Cell Therapy Pipeline

Reuters
·
Nov 07, 2025

IN8bio Inc expected to post a loss of $1.23 a share - Earnings Preview

Reuters
·
Nov 01, 2025

IN8bio Expands Inb-100 Phase 1 Clinical Trial With Addition of the Ohio State University as New Site

THOMSON REUTERS
·
Oct 29, 2025

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

GlobeNewswire
·
Oct 29, 2025

IN8bio Inc - Inb-619 Shows Equivalent Efficacy to FDA-Approved Tce Compounds

THOMSON REUTERS
·
Oct 27, 2025

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications

GlobeNewswire
·
Oct 27, 2025

IN8bio price target adjusted to $4 from $60 at Mizuho

TIPRANKS
·
Oct 13, 2025